Diversification of the vaccine development pipeline has been identified as a priority area in the Global TB Vaccine R&D Roadmap. The TBVAC-HORIZON consortium aims, amongst other things, to fill the early phases of the development pipeline while ensuring a diverse portfolio (TBVAC-HORIZON – TBVI).
One of the objectives of the project is to perform head-to-head comparisons of new candidate TB vaccines both within and outside of the consortium.
We are pleased to announce our second call for applications. This call will grant access to a head-to-head assessment of candidate vaccines. The assessment will evaluate the ability of vaccines to reduce bacterial load using a standard mouse model of vaccination and pulmonary challenge with Mycobacterium tuberculosis.
A total of four calls are foreseen within the TBVAC-HORIZON project. In the current round, there is room to asses up to six vaccine candidates in this mouse model, and we invite all who have a candidate in a relevant stage of development to submit your vaccine candidate for testing in this model.
Deadline to submit your application is August 16, 2024
For more information, please read the guidance along with supporting information and download the application form..